Baltimore, Maryland – Latham BioPharm Group (LBG), a part of Sia Partners, has been awarded a grant by the Bill & Melinda Gates Foundation to develop an easy-to-use, web-based modeling software to be used in figuring out the price of items of pharmaceutical APIs. The software will present a cheap means for all kinds of stakeholders, starting from course of scientists to authorities purchasers, to quickly consider the viability of pharmaceutical merchandise of their supposed markets, inclusive of the worth of various manufacturing approaches. LBG, in collaboration with dad or mum group Sia Partners, provides a singular functionality set that may leverage LBG’s life sciences technical consulting experience with Sia Partners’ main synthetic intelligence options (Heka.ai) and buyer expertise experience (SiaXperience) to develop this new functionality.  

“Since we initially began developing cost models with the foundation several years ago, we have realized the value of quick, consistent modeling to support pharmaceutical development decisions,” says Chris Peterson, LBG’s Director of Strategic Consulting. “This was demonstrated during COVID-19 and our modeling work on Molnupiravir specifically. Rapid development of new synthetic pathways, coupled with the ability to consistently evaluate a program’s economics, leads to the identification of significant cost reductions and the potential for greater global access from a public health standpoint. We look forward to building on this important work and making these tools more broadly accessible.”  

This mission immediately aligns with the inspiration’s public well being efforts to boost international entry to sufferers who usually want these merchandise essentially the most. Additionally, the flexibility to assist any such significant program and develop a brand new functionality/product providing is in step with LBG’s strategic dedication to function a world chief in life sciences consulting. 

To be sure that a strong necessities set is developed, the group is working with early adopters to solicit suggestions on how the modeling software could also be utilized in each international public well being and industrial pharmaceutical decision-making.